Gasporox (GAPX) uses laser-based inspection systems to test the headspace and package integrity of vials, prefilled syringes, cartridges, ampules and IV bags without damaging the product inside. The technology, which can detect leaks down to one micron at speeds of up to 600 vials per minute, was highlighted by CEO Märta Lewander Xu at the Investing in Life Science 2026 conference in Lund, Sweden.
Xu said the company’s method is cited as a recommended technique in both United States Pharmacopeia standards and EU GMP Annex 1, but acknowledged the pharmaceutical sector absorbs new inspection technologies slowly. “I would say that we are mentioned as the recommended method both in USP and in the Annex 1,” she said. “But it is a slow market to get it in.”
She added that a large share of global vaccine and injectable doses likely have passed through Gasporox equipment in manufacturing facilities. “I would dare to say that most of you have gotten injection, like a vaccine, that has been inspected by our technology,” Xu said.
Founded in 2004 as a research group initiative and launched commercially in 2011, Gasporox listed on the Nasdaq First North Growth Market in 2016. Annual turnover has hovered around 30 million kronor for roughly a decade, with 22 employees based at its Lund headquarters and production site, and an international sales organization in Switzerland.
The company entered a commercial scale-up phase in 2020 and raised capital in January 2024 to fund expansion into tablet inspection and stronger vial solutions. Its first European LineArch system installation was completed in July 2024, and CE marking for the tablet inspection product was finalized by end of 2024.
Gasporox’s portfolio spans laboratory services, benchtop units, inline sensors and full turnkey LineArch systems. Its Lab Luna offering provides testing services, expert analysis, feasibility studies and method development for clinical laboratories. The newer tablet inspection technology assesses porosity in oral solid doses, which is linked directly to dissolution rates.
The addressable pharmaceutical market comprises up to 10,000 production lines and approximately 1,000 laboratories worldwide. The food and beverage segment is roughly ten times larger, with some 100,000 beverage lines and 100,000 food production lines. Gasporox’s software is compliant with 21 CFR Part 11.
Regarding future expansion, Xu noted the company has the technical capability to grow further but requires additional capital. “I can do, but then I will need a bit more money to run this part as well,” she said.
